TH9507 Research Peptide: Tesamorelin Naming, CAS & What a COA Should Show

TH9507 is the research designation for tesamorelin, a synthetic 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification. Peptide Foundry identity anchors, naming literacy, and the purity panels to demand on a lot COA. Research use only.

Last reviewed 9 September 2026 · For research use only

CAS Number

218949-48-5

Molecular Formula

C₂₂₁H₃₆₆N₇₂O₆₇S C221H366N72O67S

Molar Mass

5135.9 g/mol

TH9507 is a research designation for a synthetic 44-residue GHRH-receptor analog commonly catalogued under the INN-style name tesamorelin. It is a discrete research material with its own CAS, formula, molar mass, N-terminal hexenoyl modification, and lot documentation — not a nickname for every GHRH-fragment listing, and not interchangeable with shorter GHRH(1-29) analogs by default.

If you found “th9507,” “tesamorelin research peptide,” “tesamorelin coa,” “th9507 peptide,” or “pf-th9507” in a listing, the useful questions are which CAS and formula the seller claims, whether the certificate describes the hexenoyl-Tyr¹ modified 44-aa sequence, whether free-base versus salt form is clear, and how the lot is documented. Aliases vary; registry fields and certificates do not.

This page covers Peptide Foundry’s published identity anchors, naming literacy (TH9507 vs tesamorelin vs out-of-scope pharmaceutical brand language; free base vs acetate), the purity panels a research buyer should demand, and a worked Freedom Diagnostics lot — then soft-handoffs to the gated TH9507 / tesamorelin research product page. Research use only.

Key points

• TH9507 = research designation for the synthetic 44-aa GHRH analog commonly named tesamorelin; N-terminal trans-3-hexenoyl modification at Tyr¹; supplied as lyophilized research material under SKU PF-TH9507 (10 mg option at publish time).
• Peptide Foundry catalog anchors (live PDP): CAS 218949-48-5, formula C₂₂₁H₃₆₆N₇₂O₆₇S, molar mass 5135.9 g/mol, PubChem 16137828 — match certificate fields to these claims.
• Demand a lot-matched COA: HPLC purity with method/wavelength when stated, identity method (MS and/or HPLC-RTM), named laboratory, and preferably independent portal verify; “99%+” without lot + named lab is unfinished.
• Related GHRH-class siblings (separate materials): sermorelin and optional co-discussion of CJC-1295 + Ipamorelin — co-listed in catalogues, not synonyms for TH9507.
• Research use only — not for human or veterinary use.

What is TH9507 / tesamorelin?

TH9507 is a forty-four-residue synthetic peptide designed as a GHRH-receptor analog. In research-vendor and registry practice the same molecule is widely indexed under the common name tesamorelin. Residue count is forty-four. The defining structural feature versus native GHRH fragments is an N-terminal trans-3-hexenoic acid (hexenoyl) acyl modification at Tyr¹ — a design choice discussed in published preclinical and in-vitro literature in the context of enzymatic-stability characterization relative to shorter unmodified scaffolds.

A short historical note anchors naming only. Development literature used the research code TH9507 for this hexenoyl-modified 44-aa construct; the INN-style name tesamorelin later became the common index term. That is origin and naming history — not a product claim and not registry proof by itself.

Physical form on research listings is lyophilized solid. Peptide Foundry’s current lot documents describe lyophilized material under SKU PF-TH9507 at a 10 mg size option. Appearance is a handling observation — not a purity proof and not a substitute for HPLC or identity data on a certificate.

Market aliases include TH9507, tesamorelin, hexenoyl-GHRH(1-44) shorthand, and informal “GHRH analog” language. Aliases help search; they are not identity proof until you have CAS, formula, molar mass, modification language, and a lot-matched certificate.

Naming literacy: TH9507, tesamorelin, and pharmaceutical brand names

Research code vs common name

TH9507 is the research / development designation. Tesamorelin is the common (INN-style) name used across registries, PubChem, and research-vendor chemistry tables for the same hexenoyl-modified 44-aa GHRH analog when CAS 218949-48-5, formula C₂₂₁H₃₆₆N₇₂O₆₇S, and molar mass near 5135.9 g/mol agree. Peptide Foundry’s research slug is th9507; the Woo product identity maps to tesamorelin, and both /product/th9507/ and the tesamorelin path resolve to the gated listing. Prefer registry fields over URL debates.

Pharmaceutical brand names (out of RUO scope)

FDA-approved pharmaceutical brand names for clinical products that use the tesamorelin active moiety exist in the wider literature index; they fall outside Peptide Foundry’s RUO catalogue scope and are not this research listing.

Free base vs acetate (sourcing check)

Some vendors list tesamorelin / TH9507 as free base, as acetate salt, or under ambiguous salt language without stating which form the certificate describes. Salt form changes formula bookkeeping and mass attribution even when sellers reuse the same marketing name.

Peptide Foundry publishes the peptide-moiety anchors CAS 218949-48-5, formula C₂₂₁H₃₆₆N₇₂O₆₇S, and molar mass 5135.9 g/mol. Read salt / counter-ion language on the lot certificate and chemistry block — do not assume every “tesamorelin” or “TH9507” label is free base. Practical rule: match salt form + formula + molar mass + modification language on the lot COA to the vendor’s chemistry table.

Chemical identity anchors

Peptide Foundry publishes a fixed identity set for single-vial TH9507 / tesamorelin. The values below match the live catalog chemistry table at the time of writing. Confirm against the current product page if a lot or chemistry block rotates after publish.

Sequence class and modification

Class: synthetic 44-aa GHRH analog. Modification: trans-3-hexenoic acid (hexenoyl) at Tyr¹. SKU PF-TH9507; size option on the live listing at publish time: 10 mg lyophilized. The sulfur atom in the published formula reflects methionine content in the 44-residue chain — confirm S appears in any formula string that claims this identity.

CAS, formula, and molar mass

Market pages sometimes round mass, omit PubChem, drop the sulfur atom, or reuse “GHRH analog” nicknames across shorter scaffolds. The practical rule is: match the vendor’s stated CAS + formula + molar mass + hexenoyl-Tyr¹ language to the lot COA, then prefer orthogonal identity (MS / HPLC-RTM) over the nickname alone.

What a TH9507 / tesamorelin COA should show

A certificate of analysis is stronger when it is lot-specific, names the laboratory, states methods, and can be checked outside the supplier’s own site. For the full verification workflow — batch match, named lab, HPLC versus identity, biosafety panels, portal codes — see How to read a research-peptide COA.

Minimum research COA fields

• A lot / batch ID that matches the vial character for character
• Test or report date(s) and a named laboratory
• HPLC purity with method (and wavelength when stated — for example 214 nm)
• An identity method (MS and/or HPLC-RTM)
• Product name / designation consistent with the label and the vendor’s published anchors (TH9507 and/or tesamorelin; hexenoyl modification when claimed)

“Third-party tested” or “99%+” without a named lab and a lot number is an unfinished claim. A pretty PDF that cannot be tied to the vial in hand is documentation theater.

Stronger panels (when claimed)

When a full QC panel is present — the pattern on Peptide Foundry’s published Freedom Diagnostics documentation — read these as separate analytical results:

• Mass-spectrometry or HPLC-RTM identity confirmation
• Net peptide content versus labeled mass when reported
• Heavy metals against stated limits
• Sterility / microbial-DNA or no-growth language when the certificate reports it
• Endotoxin (for example LAL / EU/mL limit) when claimed

These describe composition and contamination panels for research documentation. They are not a safety-for-human-use claim, and they do not replace identity or purity.

Worked example — lot FO226

As published on the current Peptide Foundry TH9507 / tesamorelin listing at the time of writing:

Cite those figures as Peptide Foundry–published transparency for this lot — not a universal industry floor. Re-verify against the live product panel if the lot rotates after publish.

Three steps that travel with any lot, not just FO226:

1. Match the lot number on the vial to the lot on the certificate.
2. Confirm CAS, formula, modification language, and labeled mass against the certificate and the product label — including free-base versus acetate language if present, and confirming sulfur in the formula.
3. Verify the access code on the issuing laboratory’s own portal (Freedom Diagnostics for FO226: access Pept2607210038) — not only by opening a PDF hosted by the supplier.

A PDF on a supplier site is a document the supplier controls. A record you can pull from the testing laboratory is not. Portable vendor criteria beyond a single SKU: USA research-peptide vendor criteria.

Related GHRH-class materials (siblings, not synonyms)

Research catalogues often co-list shorter GHRH-receptor analogs beside TH9507 / tesamorelin. Shared pathway-class language does not make the materials interchangeable. Match each vial to its own CAS, formula, residue count, and lot certificate.

Sermorelin is a different, shorter GHRH(1-29)-class research peptide. The optional CJC-1295 + Ipamorelin co-list is a blend identity problem (two analytes, DAC literacy), not a second worked example here. Soft related reading only — not a dual product CTA: CJC-1295 + Ipamorelin research identity.

Pathway-class literacy (preclinical / in vitro only)

Mechanism language is useful here only as classification of experimental systems in published literature. It does not establish catalogue-product outcomes in people, and it does not convert a citation into a certificate.

Clinical literature in wider SERPs sits outside this RUO identity page and is not summarized as product use. Keep pathway class attached to the source paper and experimental system. Identity remains CAS, formula, modification language, and the lot COA.

Storage and lab handling (lyophilized)

Standard laboratory practice for lyophilized synthetic peptides applies:

• Storage. Sealed vials at −20°C, protected from light and moisture. Lyophilized material is substantially more stable than solution.
• Temperature excursions. Brief ambient exposure in transit is normal for lyophilized material. Return vials to −20°C on arrival.
• Freeze–thaw. Minimize repeated freeze–thaw.
• Traceability. Keep the lot number with the material — lot number ties a vial back to its certificate.

Assay-specific handling follows your institution’s SOPs. This page does not publish personal reconstitution protocols for TH9507 / tesamorelin. For general lyophilized diluent literacy (BAC vs AA; no compound-specific schedules), see Lyophilized peptide reconstitution.

Common questions

Is TH9507 the same as tesamorelin?

As research designation versus common name for the hexenoyl-modified 44-aa GHRH analog — yes, when CAS 218949-48-5, formula C₂₂₁H₃₆₆N₇₂O₆₇S, molar mass near 5135.9 g/mol, and Tyr¹ hexenoyl language agree. Peptide Foundry’s research slug is th9507; the product identity also resolves under the tesamorelin Woo slug. Prefer registry fields over URL orthography.

Is this the same as pharmaceutical brand products?

No. Pharmaceutical brand products that use a tesamorelin active moiety sit outside Peptide Foundry’s RUO catalogue. This page documents research identity and lot COA literacy for gated laboratory material only.

Is TH9507 the same as sermorelin or CJC-1295 + Ipamorelin?

No. Sermorelin is a shorter GHRH(1-29)-class analog with different registry identity. CJC-1295 + Ipamorelin is a co-lyophilized two-peptide blend. Shared pathway-class language does not make materials interchangeable. Match each vial to its own CAS, formula, and certificate.

What makes a TH9507 / tesamorelin COA usable?

Lot match to the vial, a named laboratory, HPLC purity with method/wavelength when stated, an identity method (MS and/or HPLC-RTM), and preferably an independent portal verify path. Stronger documentation adds net peptide content, heavy metals, sterility, and endotoxin when claimed. Worked FO226 figures above — Freedom Diagnostics, HPLC 99.79% @ 214 nm, HPLC-RTM pass, net 11.32 mg, access Pept2607210038 — are an example of that pattern on Peptide Foundry’s live listing. Workflow detail: How to read a research-peptide COA.

Is this for human clinical-indication claims, GH-axis use in people, adipose-related product claims, personal schedules, or human use?

No. Peptide Foundry supplies TH9507 / tesamorelin strictly for laboratory and research use by qualified researchers. Mentions of GHRHR binding, somatotroph signaling, or DPP-IV / enzymatic-stability characterization in published preclinical and in-vitro literature are pathway-class context only — not product benefits and not human use. It is not a drug, supplement, or veterinary product, and not for use in people or animals. This page does not publish personal schedules, unit conversions for people, or administration-device guidance.

For the current lot certificate and product specifications, see the gated TH9507 / tesamorelin research product page. Related library reading: How to read a research-peptide COA, CJC-1295 + Ipamorelin research identity, Lyophilized diluent literacy (BAC vs AA), and USA research-peptide vendor criteria.

Research use only. Nothing on this page describes or implies use in humans or animals. Pathway-class mentions of GHRHR binding, somatotroph signaling, or DPP-IV / enzymatic-stability characterization refer only to preclinical and in-vitro literature contexts and are not product outcomes.